Artelo Biosciences (ARTL) Competitors $15.18 -0.89 (-5.54%) Closing price 04:00 PM EasternExtended Trading$15.26 +0.08 (+0.53%) As of 07:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesSEC FilingsShort InterestTrendsBuy This Stock ARTL vs. BCAB, CMMB, VYNE, AYTU, DARE, FNCH, RLMD, SLGL, DRRX, and MIRAShould you be buying Artelo Biosciences stock or one of its competitors? The main competitors of Artelo Biosciences include BioAtla (BCAB), Chemomab Therapeutics (CMMB), VYNE Therapeutics (VYNE), Aytu BioPharma (AYTU), Dare Bioscience (DARE), Finch Therapeutics Group (FNCH), Relmada Therapeutics (RLMD), Sol-Gel Technologies (SLGL), DURECT (DRRX), and MIRA Pharmaceuticals (MIRA). These companies are all part of the "pharmaceutical products" industry. Artelo Biosciences vs. Its Competitors BioAtla Chemomab Therapeutics VYNE Therapeutics Aytu BioPharma Dare Bioscience Finch Therapeutics Group Relmada Therapeutics Sol-Gel Technologies DURECT MIRA Pharmaceuticals Artelo Biosciences (NASDAQ:ARTL) and BioAtla (NASDAQ:BCAB) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, profitability, media sentiment, earnings, risk, dividends, valuation and analyst recommendations. Which has preferable earnings and valuation, ARTL or BCAB? Artelo Biosciences has higher earnings, but lower revenue than BioAtla. Artelo Biosciences is trading at a lower price-to-earnings ratio than BioAtla, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioArtelo BiosciencesN/AN/A-$9.83M-$17.94-0.85BioAtla$11M2.04-$69.78M-$1.22-0.32 Do analysts rate ARTL or BCAB? Artelo Biosciences currently has a consensus price target of $25.00, indicating a potential upside of 64.69%. BioAtla has a consensus price target of $5.00, indicating a potential upside of 1,198.70%. Given BioAtla's higher possible upside, analysts plainly believe BioAtla is more favorable than Artelo Biosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Artelo Biosciences 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 3 Strong Buy rating(s) 3.60BioAtla 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50 Is ARTL or BCAB more profitable? Artelo Biosciences' return on equity of -226.99% beat BioAtla's return on equity.Company Net Margins Return on Equity Return on Assets Artelo BiosciencesN/A -226.99% -164.61% BioAtla N/A -373.47%-116.55% Does the media prefer ARTL or BCAB? In the previous week, Artelo Biosciences had 6 more articles in the media than BioAtla. MarketBeat recorded 7 mentions for Artelo Biosciences and 1 mentions for BioAtla. BioAtla's average media sentiment score of 0.93 beat Artelo Biosciences' score of 0.42 indicating that BioAtla is being referred to more favorably in the news media. Company Overall Sentiment Artelo Biosciences Neutral BioAtla Positive Do institutionals & insiders believe in ARTL or BCAB? 0.9% of Artelo Biosciences shares are owned by institutional investors. Comparatively, 77.2% of BioAtla shares are owned by institutional investors. 0.8% of Artelo Biosciences shares are owned by insiders. Comparatively, 11.5% of BioAtla shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Which has more volatility and risk, ARTL or BCAB? Artelo Biosciences has a beta of 1.34, suggesting that its share price is 34% more volatile than the S&P 500. Comparatively, BioAtla has a beta of 0.91, suggesting that its share price is 9% less volatile than the S&P 500. SummaryArtelo Biosciences and BioAtla tied by winning 7 of the 14 factors compared between the two stocks. Get Artelo Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for ARTL and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ARTL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ARTL vs. The Competition Export to ExcelMetricArtelo BiosciencesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$8.79M$2.92B$5.57B$9.31BDividend YieldN/A2.43%4.23%4.03%P/E RatioN/A20.4928.6119.73Price / SalesN/A266.14412.31173.11Price / CashN/A43.1536.0257.96Price / Book2.867.768.235.67Net Income-$9.83M-$55.11M$3.23B$257.79M7 Day Performance-29.72%0.95%-0.01%0.52%1 Month Performance136.08%8.44%5.61%8.84%1 Year Performance90.23%-2.38%26.52%14.18% Artelo Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ARTLArtelo Biosciences2.6122 of 5 stars$15.18-5.5%$25.00+64.7%+101.4%$8.79MN/A0.005Gap UpBCABBioAtla2.0347 of 5 stars$0.39+2.6%$5.00+1,195.3%-77.5%$21.97M$11M-0.3260CMMBChemomab Therapeutics2.7661 of 5 stars$1.15-0.9%$8.50+639.1%+5.5%$21.87MN/A-1.5120Positive NewsGap UpVYNEVYNE Therapeutics2.9708 of 5 stars$1.29-9.5%$6.25+384.5%-42.7%$21.67M$500K-1.3030Positive NewsHigh Trading VolumeAYTUAytu BioPharma4.2732 of 5 stars$2.35-1.3%$10.00+325.5%-23.0%$21.41M$81M-3.26160Positive NewsDAREDare Bioscience1.8308 of 5 stars$2.40flat$12.00+400.0%-15.7%$21.24M$10K-14.1230News CoverageHigh Trading VolumeFNCHFinch Therapeutics Group0.7713 of 5 stars$13.00-0.6%N/A+707.0%$21.00MN/A-1.47190RLMDRelmada Therapeutics4.7501 of 5 stars$0.61-3.1%$5.00+719.4%-83.5%$20.91MN/A-0.2410News CoverageSLGLSol-Gel Technologies3.1752 of 5 stars$7.29-2.4%$40.00+448.7%-9.9%$20.80M$11.54M-1.5550Gap DownDRRXDURECT1.212 of 5 stars$0.64-4.0%N/A-60.7%$20.70M$1.86M-4.2780Positive NewsGap DownHigh Trading VolumeMIRAMIRA Pharmaceuticals2.433 of 5 stars$1.15-4.2%$14.00+1,117.4%+124.3%$20.30MN/A-2.252 Related Companies and Tools Related Companies BioAtla Alternatives Chemomab Therapeutics Alternatives VYNE Therapeutics Alternatives Aytu BioPharma Alternatives Dare Bioscience Alternatives Finch Therapeutics Group Alternatives Relmada Therapeutics Alternatives Sol-Gel Technologies Alternatives DURECT Alternatives MIRA Pharmaceuticals Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ARTL) was last updated on 7/16/2025 by MarketBeat.com Staff From Our PartnersElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredBuffett’s Little-Known Succession PlanYou could miss out on millions buying a house - even if prices rise Joel Litman is a millionaire member of ...Altimetry | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredSpecial gold investment soars 2,300% ... 5,090% ... 9,850%In my 54 years as an investor, I’ve seen my share of gold bull markets. But nothing comes close to the rall...Weiss Ratings | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Artelo Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Artelo Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ARTL Stock Alerts